The U.S. Court of Appeals for the Ninth Circuit dismissed a securities fraud suit against biopharmaceutical company Sorrento Therapeutics, concluding its claims that it found a "cure" for COVID-19, which led to a spike in stock prices, wasn't materially false or misleading.